Buying guide
mBos TKA System vs CORI in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
- mBos TKA System is at the research stage; CORI at the commercial stage.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Monogram Technologies | Smith+Nephew |
| Form factor | surgical | surgical |
| Maturity | research | commercial |
| Autonomy | — | ◐ not independently verified |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | Not announced | $600,000-$1,200,000 (analyst estimate) |
| Capability claims | — |
|
| Brain | — | — |
| Verified deployments | 1Ahmedabad | 1United States |
| Privacy practices | — | — |
| Sources on file | 9 | 11 |
Editorial summaries
mBos TKA System
The Monogram mBos TKA System is a robotic total-knee-arthroplasty platform from Monogram Technologies, a Zimmer Biomet subsidiary since October 2025. It is the autonomy-boundary case of DEPLOY's surgical cluster: unlike the AI-augmented, surgeon-controlled systems (Stryker Mako, Smith+Nephew CORI, Zimmer Biomet ROSA), where the surgeon makes the cuts, the cleared mBos is semi-autonomous, with a robotic arm (built on a KUKA arm) executing the bone cuts itself under AI control within a surgeon-approved, patient-specific CT-based plan and active surgeon supervision. There is no consumer price: it is pre-commercial enterprise surgical equipment that has not sold any units. Several verified-vs-claimed cap-flags matter. It received FDA 510(k) clearance on March 17, 2025, but the exact K-number could not be independently verified, and the 'semi-autonomous' characterization is sourced to Zimmer Biomet and trade coverage rather than the FDA letter (Monogram's own clearance release described it more softly as robotic-assisted TKA). A separate fully-autonomous, hands-free, saw-based version is not FDA cleared and remains in development, targeted around late 2027 or 2028; its first live-patient procedure (July 26, 2025, Ahmedabad, India) was under an India CDSCO 102-procedure investigation, not US FDA, a single index case with no verified peer-reviewed outcomes. Monogram was founded by orthopedic surgeon Dr. Doug Unis (chief medical officer and founder, not CEO; the pre-acquisition CEO was Benjamin Sexson) and was acquired by Zimmer Biomet at about $168M enterprise value plus contingent value rights, with commercialization alongside Zimmer Biomet implants targeted for early 2027. The registry records it at research maturity: cleared but pre-commercial, with its headline fully-autonomous capability still in development.
CORI
Smith+Nephew's CORI Surgical System is a compact, surgeon-controlled handheld robotics platform for orthopedic knee surgery and the handheld, imageless archetype of the orthopedic sub-cohort. It is imageless (no pre-operative CT or MRI): the surgeon paints the joint surface intra-operatively to build a 3D bone model, then uses a handheld robotic bur whose cutting speed and exposure are robotically controlled to the surgical plan, with optical navigation. Its small footprint positions it for ambulatory surgery centers and outpatient ORs. It is AI-augmented but surgeon-controlled, not autonomous. A critical verified-vs-claimed distinction aggregators routinely blur: CORI's robotic burring is cleared for the knee only (total, partial/unicompartmental, and revision knee); its hip capability is navigation-only (RI.HIP NAVIGATION, cleared January 2022), not robotic burring. Made by Smith+Nephew (LSE: SN; NYSE: SNN). As enterprise B2B surgical equipment, there is no consumer price.
Common questions
- What is the difference between mBos TKA System and CORI?
- mBos TKA System and CORI are both surgical robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.
- Is mBos TKA System or CORI more autonomous?
- On the DEPLOY registry, neither mBos TKA System nor CORI has capabilities independently verified as fully autonomous yet; their recorded capabilities are teleoperated-assisted, demonstrated, or vendor-claimed. See the table for each capability's verification status.
- Which has more verified deployments, mBos TKA System or CORI?
- mBos TKA System and CORI each have 1 verified deployment on the DEPLOY registry (confirmed at named sites with primary sources).
Recent coverage
- SK Hynix Shares Rebound After Early Rout as AI Jitters PersistCORI · Bloomberg Technology · 2026-07-14
- Class 8 truck orders soar 241% as fleets race to secure 2026 build slotsCORI · FreightWaves · 2026-07-09
- Zimmer Biomet Completes Acquisition of Monogram TechnologiesmBos TKA System · AgentRecon · 2025-10-07
- Zimmer Biomet inks 77M deal for Monogram and its hands-free orthopedic robotmBos TKA System · AgentRecon · 2025-07-14
Related comparisons
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.